CryoLife submits corrective plan to FDA:
This article was originally published in Clinica
Executive Summary
CryoLife has submitted its corrective action plan to the US FDA outlining proposed steps to validate the company's tissue processing procedures. It is currently processing tissue for use in medically urgent cases under the terms of a 45-working-day interim agreement signed on September 6 with the FDA, which also stipulated that the company draw up the action plan in collaboration with a third-party consultant or reviewer within 30 days. The agency will now decide whether to allow CryoLife to return to the market and release tissue subject to the original recall order of August 13 (see Clinica No 1027, p 17). The company's share price closed up 25% at $2.69.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.